ProfileGDS5678 / 1418421_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 79% 79% 77% 79% 80% 80% 78% 78% 82% 85% 86% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5809280
GSM967853U87-EV human glioblastoma xenograft - Control 25.5710179
GSM967854U87-EV human glioblastoma xenograft - Control 35.5492779
GSM967855U87-EV human glioblastoma xenograft - Control 45.3567377
GSM967856U87-EV human glioblastoma xenograft - Control 55.4842479
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4733880
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5703780
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2975278
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3970478
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9750782
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3744185
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5417986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3678385
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.406385